Latest Japan Approvals Include Evrysdi For SMA
Plus Global First For Imeglimin
Executive Summary
Japan's latest batch of product approvals includes the country's second therapy for SMA and the first nod globally for a novel antidiabetic.
You may also be interested in...
New Hope, Funding Approaches As Roche Brings Evrysdi To India
Roche’s Evrysdi debuts in India backed by a patient support program ahead of Novartis’ Zolgensma and Biogen’s Spinraza. Spotlights remains on the price tag for the SMA therapy amid hopes that novel approaches such as crowdfunding could also broaden access.
Poxel/Sumitomo's Novel Diabetes Therapy Imeglimin Nears Japan Market
Poxel’s potential first-in-class diabetes therapy, imeglimin, could be approved in Japan this year, and a new partner is being sought for the EU and US – events that would transform the outlook for the decade-old Merck Serono spin-out.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Amgen launches first US biosimilar to Humira; strong launches set to help BMS as it faces losses of exclusivity; Eisai preaches patience on Leqembi for Alzheimer’s; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.